 (CIndU) has long lacked approved therapies, leaving clinicians to rely on up-dosed antihistamines and off-label agents for a frequently persistent disease.

In this HCPLive Special Report, Andrea Nguyen, DMSc, MPAS, PA-C, of First OC Dermatology, spoke with Adam Friedman, MD, of George Washington University School of Medicine and Health Sciences, about how the approval of remibrutinib (Rhapsido),  an oral Bruton tyrosine kinase (BTK) inhibitor, for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.

Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism, and its role in chronic inducible urticaria.

Special Report: Remibrutinib, an Oral BTKi, for Chronic Inducible Urticaria

In the phase 3 RemIND trial, 115 adults with a mean disease duration of 5.8 years received remibrutinib 25 mg or placebo twice daily. At week 12, 29.3% (17/58) vs 14.0% (8/57) achieved a complete response on the Total Fric Score (P = .0229). Responses emerged by week 2, persisted through week 24, and held regardless of baseline total IgE.

A complete response means no wheal after standardized friction provocation, a stringent bar in easily provoked skin. This consistency across IgE levels supports broad applicability, unlike CSU, where IgE can predict response to omalizumab (Xolair).

Remibrutinib blocks BTK downstream of high-affinity IgE receptor cross-linking, halting mast cell degranulation whether activation is IgE- or IgG-mediated. Its efficacy in dermographism also suggests a BTK role in inducible mast cell activation.

Safety mirrored the REMIX trials in CSU, where petechiae occurred more often with remibrutinib than placebo (3.8% vs 0.3%).

 Mild mucocutaneous bleeding reflects BTK's role in platelet function, and no routine laboratory monitoring is required.

Collectively, the approval gives clinicians evidence-based footing in a long-neglected condition. Data from cold and cholinergic urticaria cohorts may extend the reach of BTK inhibition further.

Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. 

Novartis. Novartis Rhapsido (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU). Published October 7, 2026. Accessed October 7, 2026. 

https://www.novartis.com/us-en/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu

Videos

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Joy Chang, MD, MS, is an assistant professor of medicine in the division of gastroenterology at the University of Michigan in Ann Arbor.

Improving Diagnostic Evaluation in EoE

In this episode, ‘Improving Diagnostic Evaluation in EoE,’ the panelists explore how clinicians can recognize patients who warrant evaluation for eosinophilic esophagitis and improve the quality of the diagnostic workup. The experts emphasize that dysphagia and food impaction should clearly prompt further investigation, but adaptive eating behaviors may provide subtler clues. Patients may avoid problematic foods or normalize abnormal swallowing patterns because similar behaviors have developed gradually or are shared by family members.

The discussion then focuses on endoscopic evaluation. The panel explains that clinicians should assess for inflammatory findings such as edema, furrows, and exudates, as well as rings, strictures, reflux-related changes, and other potential causes of dysphagia. Importantly, a normal-appearing esophagus does not exclude EoE. Faculty stress that biopsies remain essential because disease can be patchy and visually subtle. They discuss obtaining multiple biopsies from different levels of the esophagus and using standardized EREFS documentation to objectively track endoscopic findings over time.

The experts also identify food impaction as an important diagnostic opportunity that is too often missed, particularly during urgent procedures. Failure to obtain biopsies may lead to patients being lost to follow-up once the acute obstruction is relieved. The panel highlights practical strategies for improving biopsy rates and emphasizes that systematic evaluation can shorten the interval between symptoms and diagnosis.

The next episode in this series, ‘Recognizing Progression and Fibrostenotic Disease in EoE,’ features the panelists discussing demographic misconceptions, diagnostic delay, and the

relationship between persistent inflammation and fibrostenotic progression.

Early EoE recognition depends on looking beyond overt dysphagia and performing an adequate diagnostic evaluation. Careful endoscopy and appropriately distributed biopsies can prevent missed opportunities for diagnosis.

Video Series

Understanding Epithelial Dysfunction and Symptom Adaptation in EoE

Welcome back to another HCP Live Peer Exchange series. In this episode titled, ‘Understanding Epithelial Dysfunction and Symptom Adaptation in EoE,’ the panel of experts examines the evolving understanding of eosinophilic esophagitis pathophysiology and the factors that contribute to delayed recognition of disease. The faculty discuss the esophageal epithelium as an active component of immune function rather than simply a passive barrier, emphasizing the bidirectional relationship between epithelial injury and type 2 inflammation. They explain how this broader understanding has shifted attention beyond the eosinophil toward upstream inflammatory pathways and other potential therapeutic targets.

The panel then explores why EoE care frequently remains symptom-driven despite the underlying chronic disease process. Faculty highlight barriers to specialty care and the challenge of relying on patients to recognize and report symptoms that may have developed gradually. They emphasize that patients often normalize dysphagia and develop compensatory eating behaviors, including drinking excessive fluids with meals, avoiding certain foods, chewing extensively, or taking longer to eat. Family members may recognize these changes before patients themselves appreciate their significance. The experts stress the importance of asking detailed questions about eating patterns and adaptive behaviors to uncover disease burden that may otherwise remain hidden.

In the next episode, ‘Improving Diagnostic Evaluation in EoE,’ panelists will continue their discussion on EoE and highlight clinical presentations that should prompt evaluation, along with best practices for endoscopy and esophageal biopsy.

EoE extends beyond eosinophilic inflammation, with epithelial barrier dysfunction helping perpetuate disease activity. Recognizing how patients adapt to chronic symptoms may be equally important for identifying disease earlier.

Michael Wechsler, MD, of National Jewish Health.

 who reached clinical remission with twice-yearly depemokimab (Exdensur) in year 1 had fewer exacerbations and greater lung function gains in year 2, according to an integrated analysis presented at the 

Depemokimab, an ultra-long-acting interleukin-5 (IL-5) antagonist, received FDA approval in December 2025 as add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 years and older.² In the 52-week phase 3 SWIFT-1/-2 trials, 29% of patients receiving depemokimab achieved 4-component clinical remission at week 52, compared with 23% of patients receiving placebo.¹ The new analysis asked whether remission status at the end of year 1 carried forward into a second year of continuous treatment.

“If you can achieve remission with a specific therapy, you’re more likely to continue to stay in remission,” said Michael E. Wechsler, MD, MMSc, professor of medicine and director of The Cohen Family Asthma Institute at National Jewish Health. “It gives [us] confidence that the therapy is working and that patients will continue to do well with that therapy.”

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes

Depemokimab Clinical Remission Durability in SWIFT and AGILE

The integrated post hoc analysis included patients who received depemokimab across both the SWIFT-1/-2 trials and the 52-week AGILE open-label extension study.¹ Investigators defined 4-component clinical remission as no exacerbations across 52 weeks, no maintenance oral corticosteroid use in the final 90 days, an Asthma Control Questionnaire (ACQ)-5 score < 1.5, and a change from baseline in forced expiratory volume in 1 second (FEV1) of ≥ 0 mL.¹

Of 419 patients treated with depemokimab in both years, 405 entered the clinical remission analysis set.¹ A total of 30% (123/405) achieved clinical remission at the end of year 1, and 59% (73/123) of these patients maintained remission at the end of year 2.¹ The remaining 70% did not reach remission in year 1.¹

During year 2, the annualized exacerbation rate was 0.19 (95% CI, 0.12–0.29) among patients in remission at year 1, compared with 0.69 (95% CI, 0.57–0.82) among patients not in remission.¹ Wechsler noted patients who sustained remission into year 2 had no exacerbations, stable or improved lung function, no significant symptoms, and no steroid use for asthma.

Depemokimab Year 2 Outcomes in FEV1, ACQ-5, and SGRQ Scores


Depemokimab (Exdensur) is FDA approved as add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 years and older, dosed by subcutaneous injection twice yearly.²


Depemokimab is an ultra-long-acting monoclonal antibody with enhanced IL-5 binding affinity and an extended half-life, which reduces eosinophilic inflammation and allows dosing every 6 months.¹

What did the SWIFT/AGILE remission analysis show?


Of patients in clinical remission at the end of year 1, 59% remained in remission at year 2, with a year 2 annualized exacerbation rate of 0.19 vs 0.69 in patients not in remission.¹

Patients achieving remission at the end of year 1 showed greater improvements across all 3 secondary outcomes at the end of year 2, measured as least squares mean change from SWIFT-1/-2 baseline.¹ St George’s Respiratory Questionnaire (SGRQ) total score improved by −23.57 points (95% CI, −26.53 to −20.62) in the remission group vs −13.15 points (95% CI, −15.13 to −11.17) in the nonremission group.¹

ACQ-5 score changed by −1.34 (95% CI, −1.51 to −1.17) in patients with year 1 remission vs −0.71 (95% CI, −0.82 to −0.60) in patients without remission.¹ Pre-bronchodilator FEV1 improved by 379 mL (95% CI, 301–458) vs 85 mL (95% CI, 33–137), respectively.¹ The trend remained consistent at every assessed timepoint during year 2.¹

Wechsler emphasized the 70% of patients not meeting the 4-component definition in year 1 may still benefit from continued treatment. He described remission as a high bar and noted ongoing debate among experts on which components and what duration should define it.

“Not everyone’s going to achieve remission, but they might still have benefits,” Wechsler said. “They might have benefits in terms of reduction in steroid dose, reduction in exacerbations, improvement in lung function, [and] improvement in symptoms.”

He added a 3-component definition without a lung function criterion may better fit patients with a near-normal baseline FEV1, for whom eliminating prior exacerbations is the more meaningful outcome.

“Sometimes some people start off [with] a high lung function,” he said. “If their FEV1 is 85%, they may not necessarily improve in terms of lung function. Whereas if they had two exacerbations in the year prior, that is important.”

Editor’s note: Reported disclosures for Wechsler include GENZYME CORPORATION, GlaxoSmithKline, Regeneron Healthcare Solutions, and more.

Wechsler ME, Tacon CE, Muccino D, et al. Attainment of clinical remission with twice-yearly depemokimab in year 1 is associated with improved clinical outcomes in year 2: SWIFT/AGILE integrated analysis. Presented at: CHEST 2026; October 20, 2026; Phoenix, AZ.

GSK. Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma. Published December 16, 2025. Accessed October 21, 2026. 

https://www.businesswire.com/news/home/20251216764904/en/Exdensur-depemokimab-approved-by-US-FDA-for-the-treatment-of-severe-asthma

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Frank Sciurba, MD, professor of medicine at the University of Pittsburgh School of Medicine.

An analysis of the phase 3 OBERON and TITANIA trials presented at the 

 in Phoenix found tozorakimab improved patient-reported daily respiratory symptoms vs placebo in patients with 

Full results presented at the European Respiratory Society (ERS) Congress 2026 showed tozorakimab, an investigational anti-interleukin-33 (IL-33) monoclonal antibody, reduced moderate to severe exacerbations by 29% in OBERON and 34% in TITANIA among former smokers, the primary population.²,

 In the overall population of current and former smokers, reductions were 30% and 29%, respectively.² The new analysis asked whether the exacerbation benefit extends to how patients feel day to day.

“Exacerbations are really important events in these patients’ lives, resulting in hospitalization, leading to other downstream effects, including death,” said lead investigator Frank Sciurba, MD, professor of medicine at the University of Pittsburgh School of Medicine and director of the Emphysema COPD Research Center, in an interview with 

. “Patients do want to feel better, independent of [exacerbation] risk reduction.”

Toztorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA

Tozorakimab E-RS:COPD Results in OBERON and TITANIA

Sciurba and colleagues analyzed 1750 current and former smokers randomized to subcutaneous tozorakimab 300 mg (n = 446 in OBERON; n = 438 in TITANIA) or placebo (n = 431; n = 435) every 4 weeks for up to 52 weeks.¹ The team assessed change from baseline in the Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score (range, 0 to 40) and its subdomains for breathlessness, cough/sputum, and chest symptoms.¹ Daily scores were aggregated into 14-day intervals and analyzed with a repeated measures model.¹

Full data from the phase 3 OBERON and TITANIA trials were presented at the European Respiratory Society (ERS) Congress 2026: 

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD

Baseline mean E-RS:COPD total scores ranged from 14.4 to 15.2 across arms.¹ At week 52, the least-squares (LS) mean change from baseline was −2.31 (95% CI, −2.94 to −1.67) with tozorakimab vs −1.41 (95% CI, −2.05 to −0.77) with placebo in OBERON.¹ In TITANIA, the corresponding changes were −1.92 (95% CI, −2.45 to −1.40) and −0.84 (95% CI, −1.37 to −0.32), for LS mean differences vs placebo of −0.90 (95% CI, −1.54 to −0.26) in OBERON and −1.08 (95% CI, −1.66 to −0.50) in TITANIA.¹

Separation emerged after the first dose. At week 4, the LS mean difference was −0.62 (95% CI, −1.22 to −0.03) in TITANIA and −0.68 (95% CI, −1.40 to 0.04) in OBERON, where the CI crossed 0.

Sciurba said the early timepoint was not powered for significance and noted the effect broadened across the 52-week treatment period.

Tozorakimab Effects on Breathlessness, Cough, and Chest Symptoms

What did the OBERON and TITANIA symptom analysis show?


Tozorakimab 300 mg every 4 weeks improved E-RS:COPD total scores vs placebo at week 52 in both trials, with improvements in breathlessness, cough/sputum, and chest symptoms.¹


Tozorakimab blocks IL-33, an upstream cytokine released from damaged airway epithelium, affecting type 2 and non-type 2 inflammatory pathways. According to Sciurba, it also limits conversion of IL-33 to its oxidized form, which signals through RAGE/EGFR to drive epithelial remodeling and mucus hypersecretion.


No. The FDA is reviewing tozorakimab for COPD under Priority Review, with a decision anticipated in the first quarter of 2027.²

Tozorakimab improved all 3 E-RS:COPD subdomains vs placebo at 52 weeks.¹ In OBERON, LS mean differences were −0.36 (95% CI, −0.66 to −0.05) for breathlessness, −0.16 (95% CI, −0.31 to −0.02) for cough/sputum, and −0.27 (95% CI, −0.44 to −0.09) for chest symptoms.¹ TITANIA showed differences of −0.38 (95% CI, −0.64 to −0.12), −0.18 (95% CI, −0.31 to −0.06), and −0.31 (95% CI, −0.47 to −0.15), respectively.¹

In the pooled population, total score changes favored tozorakimab across screening blood eosinophil subgroups: −0.60 (95% CI, −1.20 to 0.01) for < 150 cells/µL, −0.82 (95% CI, −1.30 to −0.33) for ≥ 150 cells/µL, and −0.71 (95% CI, −1.47 to 0.06) for ≥ 300 cells/µL.¹ Sciurba said symptom benefit was also consistent across lung function severity, chronic bronchitis status, and smoking status. He noted exacerbation reductions of about 23% in patients with fewer than 150 eosinophils/µL and about 43% in those with 300 cells/µL or more.

Placebo groups also improved across 52 weeks, a pattern Sciurba attributed to the placebo effect and regression to the mean common in COPD trials. He emphasized the separation between arms, which he described as early and durable through week 52. Sciurba also called the consistency across smoking status unexpected, since earlier data with a competing IL-33 pathway agent suggested reduced efficacy in active smokers.

“In patients who have a history of frequent exacerbations, this drug offers not only in the Th2-high space another potential product to try, but also in a space where there currently is a large unmet need,” Sciurba said. “It reduces exacerbation risk but also improves symptoms, which is important to patients in both Th2-high and Th2-low subgroups.”

AstraZeneca reported tozorakimab was generally well tolerated in both trials.² The FDA accepted the company’s Biologics License Application for tozorakimab 300 mg as add-on maintenance treatment for adults with COPD under Priority Review, with a decision anticipated in the first quarter of 2027.²

Sciurba’s disclosures include AstraZeneca and others.

Sciurba FC, Bhatt SP, Watz H, et al. Tozorakimab treatment improves daily respiratory symptoms in patients with chronic obstructive pulmonary disease: results from the OBERON and TITANIA studies. Presented at CHEST Annual Meeting 2026; October 18-21, 2026; Phoenix, AZ.

Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA phase III trials. AstraZeneca. Published September 8, 2026. Accessed October 21, 2026. 

https://www.astrazeneca.com/media-centre/press-releases/2026/tozorakimab-demonstrated-statistically-significant-highly-clinically-meaningful-reduction-copd-exacerbations-oberon-titania-phase-iii-trials.html

Sciurba F. Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD. HCPLive. Published September 8, 2026. Accessed October 21, 2026. 

https://www.hcplive.com/view/tozorakimab-cuts-copd-exacerbations-across-eosinophil-levels

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Articles

AAD and HSF issued the first joint hidradenitis suppurativa guidelines, outlining 37 recommendations and flagging step therapy as a major barrier.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk

Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.

BIOX-101 Displays Safety and Efficacy in Spontaneous Intracerebral Hemorrhage

A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.

Stroke Etiology Modifies Tenecteplase’s Effect Before Endovascular Thrombectomy

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.

CHEST 2026: Day 3 Recap — 6 Headlines to Know

Associate professor in the Division of Pulmonology and Department of Internal Medicine at the Medical University of Graz in Austria

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD

Professor, University of Kiel, Kiel, Germany | Medical Director, Velocity Clinical Research Grosshansdorf, Grosshansdorf, Germany

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD

At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs. 

Q&A: Curcumin Lowers IL-17 in COPD, With Retno Ariza Soemarwoto, MD

Jean Bourbeau, MD, professor of medicine at McGill University.

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

FDA approves bepirovirsen after phase 3 trials show 19% achieved functional cure at 24 weeks off all hepatitis B treatment.

Infectious Disease

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on viruses, infections, and bacteria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for COVID-19, influenza, vaccine-preventable diseases, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Latest News

Special Report: Remibrutinib, an Oral BTKi, for Chronic Inducible Urticaria

Improving Diagnostic Evaluation in EoE

Understanding Epithelial Dysfunction and Symptom Adaptation in EoE

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA